|
Avedro, Inc
Ticker Symbol: AVDR* CUSIP: 05355N109 Exchange: NGM
* NOTE: This security is no longer trading as of 11/21/2019
Company's Online Profile
BUSINESS: Avedro, Inc is a leading commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or contact lenses.
|
Notes: November 21, 2019 -- pursuant to the terms and conditions of an Agreement and Plan of Merger, dated as of August 7, 2019, by and among Glaukos Corporation, a Delaware corporation, Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Glaukos (“Merger Sub”) and Avedro, Inc., a Delaware corporation (“Avedro”), Merger Sub was merged with and into Avedro, with Avedro continuing as the surviving corporation and a wholly owned subsidiary of Glaukos.
At the effective time of the Merger, each share of common stock, par value $0.00001 per share, of Avedro, (other than shares of Avedro Common Stock owned by Glaukos, Merger Sub, Avedro or any direct or indirect, wholly owned subsidiary of Avedro or Glaukos) that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 (the “Exchange Ratio”) of a share of common stock of Glaukos, par value $0.001 per share (“Glaukos Common Stock”).
|
IPO - 2/14/2019 - 5.00 Million Shares @ $14.00 /share.
Link to IPO Prospectus
Small Cap Stock -
Market Value $144.0 Million
|
Company's Online Information Links
|
| Company's Online SEC EDGAR Filings |
| Company's Email Address Links |
| Address and Phone Numbers |
| Address: 201 Jones Road, Waltham, MA 02451 |
| Main Phone Number |
781-768-3400 |
| Fax Number |
Not Available |
| Investor Contact
Greg Chodaczek
|
646-924-1796
|
| CEO - Reza Zadno |
CFO - Thomas E. Griffin |
Find a problem? Please use our Feedback Page or Email us.
Have you filled out our Guestbook? If not, please do.
|
|
